Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Earmarks $11.8 Billion for Drug Innovation in 2016-2020 Five-Year Plan

publication date: Jun 29, 2012
China plans to spend 75 Billion RMB ($11.8 billion) to increase biopharma innovation in its 13th Five-Year Plan, which covers the period 2016-2020. That is almost double the 40 billion RMB ($6.3 billion) it will spend in the current period, the 12th Five-Year Plan for 2011-2015, bringing its ten-year total to over $18 billion. The news was delivered by Chen Zhu, China’s Minister of Health, who was speaking recently at the BioChina Convention. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital